The treatment program for mesothelioma depends on many factors, including: the stage of the cancer, where the cancer is, how far the cancer has spread, how the cancer cells look under the microscope and the patient’s age and desires.
TIME MATTERS
People diagnosed with this disease are often told the expected survival rate is only eight to twelve months. However, specialists in treating malignant mesothelioma at the leading cancer centers often have better statistics.
For instance, the five-year survival rate has approached 40% for selected patients of Dr. David Sugarbaker at Brigham and Women’s Center in Boston. To qualify for Dr. Sugarbaker’s treatment you must meet certain criteria. One of them is being in the early stages of the disease, so time is of the essence. To find out more about Dr. Sugarbaker and other physicians and cancer centers specializing in mesothelioma click on Finding Specialists.
Click here for an article by Dr. David J. Sugarbaker that appeared in the The Journal of Thoracic and Cardiovascular Surgery, January 1999 (12 pages in Adobe PDF format).
TRADITIONAL CARE
There are three traditional kinds of treatment for patients with malignant mesothelioma:
Surgery (taking out the cancer) Chemotherapy (using drugs to fight the cancer) Radiation Therapy (using high-dose x-rays or other high-energy rays to kill cancer cells) Often two or more of these are combined in the course of treatment.
MESOMARK BLOOD TESTNEW!
In January 2007, the Food and Drug Administration (FDA) approved the MESOMARK assay to help monitor response to treatment in epithelial and bi-phasic malignant mesothelioma patients. A specific protein, or biomarker, called Soluble Mesothelin-Related Peptide (SMRP), may be released into the blood by mesothelioma cancer cells. By measuring the amount of SMRP in a blood sample, doctors may be able to better monitor a patient's progress. Based on the limited amount of data currently available, use of this test may be beneficial, but effectiveness has not been determined at this time. The MESOMARK blood test has NOT yet been approved for the early diagnosis of mesothelioma.
This test has been approved as a Humanitarian Use Device (HUD), meaning that physicians must follow certain procedures to qualify their patients for testing. Once the physician is certified, informational brochures will be sent to be distributed to each applicable patient.
Those wishing to take part in MESOMARK testing will be asked to provide one or more samples of blood. The blood samples will then be sent to a national reference laboratory for testing. In conjunction with other clinical and laboratory data obtained by your doctor, decisions regarding your treatment and care may be simplified. You may discontinue testing at any time.
The costs associated with the MESOMARK blood test may not be covered under health insurance, therefore, you may be required to pay all or part of the costs out of pocket. It is recommended that you check with your insurance carrier to determine whether coverage is available under your policy.
SURGERY
Diagnostic Procedures As previously mentioned in the "Symptoms" section of this website, a diagnosis of mesothelioma from fluid is many times inconclusive. Given this fact, diagnostic surgery becomes a necessary next step in confirming and staging mesothelioma.
Thoracoscopy enables a physician to evaluate the pleural cavity and to conduct multiple tissue biopsies under direct vision. In up to 98% of cases, a definitive diagnosis can be obtained. Often, chemical pleurodesis aimed at relieving the accumulation of fluid in the intrapleural space, can be accomplished during the same procedure. It is also possible to gauge the extent of the tumor, and make a determination of surgical resectability. While less invasive than an open biopsy, it can only be performed on patients where tumor has not obliterated the pleural space.
VATS, or video-assisted thoracic surgery is an alternative to thoracoscopy, although because of its more invasive nature, concerns of tumor seeding increase. By utilizing small incisions, the physician can view the pleural space with the assistance of a camera, and obtain sufficient tissue samples for analysis by a pathologist. Extent of the tumor (i.e., pleural involvement, chest wall invasion) may also determined, and recommendation as to the type of debulking procedure necessary can be made at this time.
Mediastinoscopy is sometimes used as an aid in staging extent of disease when enlarged nodes are seen using imaging techniques.
Laproscopy is used in mesothelioma patients in cases where imaging techniques suggest possible invasion of the tumor through the diaphragm. This information can be important in evaluating a patient for potential pleurectomy or extrapleural pneumonectomy.
Palliative Procedures Palliative surgical procedures are those which treat a symptom of mesothelioma, without aggressively treating the disease itself.
Chest Tube Drainage and Pleurodesis is considered the most common of palliative treatments. Fluid build-up, or pleural effusion, is most often the first symptom which will prompt mesothelioma patients to seek medical attention. Once this effusion has occurred, it is many times persistent, returning rapidly after initial thoracentesis (draining of the fluid). In order to eliminate this problem, the pleural space must be closed. This is accomplished by use of a talc slurry or other sclerosing agent which produces an adhesion.
Thoracoscopy and Pleurodesis is done in conjunction with VATS using a powdered form of talc versus talc slurry. Both this and chest tube drainage and pleurodesis will be only effective if there is no tumor encasing the lung which restricts its expansion.
Pleuroperitoneal Shunt plays a limited role in palliation for several reasons. It involves placement of a catheter run under the skin from the pleural to the peritoneal cavity. Obstruction of the catheter and possible seeding of the tumor into the abdominal cavity may be concerns.
Pleurectomy, used as a palliative procedure, may be performed where more extensive surgery is not an option. In these cases, it is understood that all visible or gross tumor will not be removed. It is considered the most effective means of controlling pleural effusion in cases where the lung's expansion is restricted by disease.
Potentially Curative Procedures These procedures are performed with "curative intent". Their goal is removal of all gross disease, with the knowledge that microscopic disease will most likely remain. Adjuvant therapy (another form of treatment in addition to the primary therapy) is typically aimed at eliminating residual disease.
For Pleural Mesothelioma: Pleurectomy/Decortication is usually performed on patients with early stage disease (Stage I and selected Stage II), and attempts to remove all gross tumor. If it is found that all tumor can not be removed without removing the lung, this may be done at the same time and is called pneumonectomy.
Extrapleural Pneumonectomy is considerably more radical than other surgical approaches, and should be carried out by surgeons with great expertise in evaluating patients and performing the procedure itself. (See Finding Specialists.) Because in the past surgery alone has failed to effect a cure, or even to help prolong life for any extended period of time, it is currently being combined with traditional chemotherapy and/or radiation, or other new approaches such as gene therapy, immunotherapy or photodynamic therapy.
General Patient Selection Criteria for Extrapleural Pneumonectomy
Extrapleural pneumonectomy is a serious operation, and doctors experienced in this procedure choose their patients carefully. It is up to each individual surgeon to advise the patient on its feasibility and to conduct whatever tests he/she feel are necessary to optimize the patient=s chances for survival and recovery. Following is a general list of patient selection criteria. This list may not be all inclusive, and may vary according to the preference of the surgeon.
Karnofsky Performance Status score of >70. This score relates to what symptoms of disease the patient may be experiencing and how well they are able to conduct their daily activities. Some surgeons may require a higher performance status than others. Adequate renal (kidney) and liver function tests; no significant kidney or liver disease. Normal cardiac function per electrocardiogram and echocardiography. Adequate pulmonary function to tolerate the surgery. Disease limited to the ipsilateral hemithorax (the same side of the chest in which the mesothelioma is located) with no penetration of the diaphragm, extension to the heart or extensive involvement of the chest wall. Age of the patient is taken into consideration, but may not be as important as their overall status.
Surgeries of this nature should always be done with a complete understanding of the possible benefits and risks involved. If you are considering surgery as a treatment option, speak openly with your doctor about your concerns, and be sure all of your questions are answered to your satisfaction.
For Peritoneal Mesothelioma: Cytoreductive Surgery is aimed at removing all or nearly all of the gross or visible tumor in the peritoneal cavity. In order to treat any remaining cancer cells, Intra-Peritoneal Hyperthermic (heated) Chemotherapy (IPHC) is then delivered to the abdominal cavity. The type of chemotherapy drug used may vary according to the physician’s preference. Click here for more on treatment of peritoneal mesothelioma. TOP
CHEMOTHERAPY
Chemotherapy is defined as the treatment of cancer using chemical substances. When cancer occurs, abnormal cells continue to divide uncontrolled. Anticancer, or chemotherapy drugs, work to destroy cancer cells by preventing them from multiplying. Read more on types of chemotherapy medicines.
Purposes of ChemotherapyChemotherapy may be used to achieve different goals, depending on the stage of the cancer at the time of diagnosis and the age and health of the patient. Since chemotherapy for mesothelioma is not considered "curative", the goal is:
To control the cancer by stopping its spread or slowing its growth. To shrink tumors prior to other treatments, such as surgery. This is called neoadjuvant chemotherapy. To destroy microscopic disease which may remain after surgery. This is called adjuvant chemotherapy. To relieve symptoms, such as pain. This is called palliative chemotherapy, and is given in cases when a drastic reduction in the tumor is not expected. The most common use for chemotherapy in mesothelioma patients, is as an option for those who are not surgical candidates, however, various cancer centers are now conducting trials using the neoadjuvant approach. Alimta (pemetrexed) is a new drug recently approved by the Food and Drug Administration (FDA) for use with Cisplatin in the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are not candidates for curative surgery. Alimta is the first drug approval specific to mesothelioma.
The Alimta/Cisplatin chemotherapy regimen is the first Food and Drug Administration (FDA) approved treatment specifically for malignant pleural mesothelioma. This is currently considered the most effective first-line treatment for mesothelioma patients who are not surgical candidates. A multi-targeted antifolate drug, Alimta works by blocking the enzymes necessary for DNA copying and cell division. During the clinical trial process, Alimta/Cisplatin improved median survival for pleural mesothelioma patients by approximately three months over treatment with Cisplatin as a single agent. Eli Lilly's information on treatment with Alimta.
As with any medical treatment, it is important to discuss the use of Alimta with your doctor. This conversation should include all pertinent information regarding effectiveness, administration and possible side effects of the drug combination. It is also important to begin vitamin supplementation of B12 by injection during the week prior to treatment (to be repeated every 9 weeks), and folic acid by mouth daily (to be continued until 21 days after the last cycle of Alimta). Additionally, you will be given an oral steroid medication to minimize the risk of skin rash or other possible side effects. Your doctor will have information on the correct dosages of each medication. Be sure to tell your doctor of any other medications you are taking (including non-prescription drugs) so he may be aware of any adverse interactions.
Alimta/Cisplatin is administered to patients on an outpatient basis every 21 days. This cycle of treatment involves a 10-minute IV infusion of Alimta followed by a 2 hour infusion of Cisplatin. How many cycles of treatment you receive will be dependent on your response rate to the drug (regression of the tumor or halt to progression of the disease) and the side effects you might experience.
Side effects of Alimta/Cisplatin are mild to moderate for most mesothelioma patients, i.e., nausea, vomiting and fatigue, and can usually be managed by your doctor. For some patients, however, side effects may be debilitating, and may require a decrease in dosage or removal from the program. All potential side effects should be mentioned to your doctor. Never assume any complaint is minor.
Administration of ChemotherapyThe most common way to administer chemotherapy is intravenously, or through a vein. A thin needle is inserted into a vein in the hand or in the lower arm. Intravenous administration of drugs allows for rapid entry into the blood stream. Drugs may also be delivered via catheters and/or ports.
Catheters are soft, thin, flexible tubes placed into a large vein in the body. They remain in place for as long as they are needed. The catheter may sometimes be attached to a port, a small round plastic or metal disc placed under the skin on the chest. Ports also remain in place for as long as necessary. Intraperitoneal chemotherapy may also be delivered through a catheter or a port. The catheter is inserted through the abdominal wall. Chemotherapy drugs can then be infused directly into the abdominal cavity. Ports may also be placed under the skin of the abdominal wall and the catheter tunneled between the skin and muscle into the peritoneum.
Side Effects of ChemotherapyCancer cells grow and divide more rapidly than normal cells, but some normal cells also multiply quickly, particularly those in the digestive tract, reproduction system, and hair follicles. It is the damage done to normal cells that causes side effects. The type of side effects you might experience and how severe they are, depend on the type of chemotherapy you are receiving, the dosage given and how your own body reacts. Before beginning any chemotherapy treatment, you will be asked to sign a consent form. Before signing the form, be sure your doctor informs you of all the facts regarding the treatment he/she will be administering, including information about the particular drug or combination of drugs to be used, the possible risks or side effects, the number of treatments you will receive and how often, and whether it will be given during a hospital stay or on an outpatient basis. More on anti-nausea treatment for chemotherapy patients.
vendredi 1 février 2008
mesothelioma doctor
mesothelioma doctor
When you have been diagnosed with a rare form of cancer such as mesothelioma, finding a doctor who is familiar with the disease and its treatment is an important consideration. Health care available at the local level may suffice if you choose “standard” care options such as chemotherapy, however, if you are looking into surgical evaluation or other specialized forms of treatment, it becomes more important to expand your search for doctors who deal with mesothelioma on a regular basis and have experience in the most up to date protocols available.
Second opinions are common when dealing with a rare cancer, and after listening carefully to your primary doctor’s opinions and treatment plans, you may wish to consult with a more specialized physician before making a treatment decision. By doing this, you can feel comfortable that you have explored every avenue possible and have information on every available option. Your primary doctor may be able to refer you to a specialist, or you can do this on your own as a “self referral”. In either case, you should be sure your primary doctor is aware that you are satisfied with the care you have been given thus far, but because of the rarity of the disease, you would like to be as thoroughly informed as possible. No good doctor should feel threatened that you want to seek a second opinion – it is simply being a good consumer.
A “specialist” is a physician who is licensed to practice medicine, has met certain education and training criteria in a specific field and has passed an examination given by a specialty board. These doctors are then “board certified” in their field. A physician may also choose a “subspecialty” to further increase their expertise and become board certified in the subspecialty as well. Nearly all board certified specialists are members of a medical specialty society that relates to their field of specialization.
Following are some examples of specialties and subspecialties as applies to mesothelioma treatment:
Surgery is a specialty that pertains to the treatment of disease by surgical operation on any area of the body. Doctors who conduct these types of surgeries are called general surgeons. An example of a surgical subspecialty would be a thoracic surgeon who deals specifically with diseases of the chest area. Medical Oncology is a subspecialty of internal medicine. Medical oncologists treat cancer and most often manage treatment plans such as chemotherapy. They may also consult with or refer to other types of specialists. Radiation Oncology is a subspecialty of radiology. Radiation oncologists specialize in the use of radiation to treat cancer. In order to make an informed decision when choosing your doctor, consider the following questions:
Does the doctor have the education and training necessary to meet my needs, and does he or she have experience in treating mesothelioma? How many cases of mesothelioma has he or she treated in the past year? In their career? Has the doctor given you information on mesothelioma itself, and on the various treatment options you might be eligible for? Does the doctor listen to your concerns and treat you with respect? Does the doctor encourage you to ask questions and explain things in terms that you understand? When choosing a surgeon, considering the following questions:
Is the surgeon board certified? Does the surgeon belong to a medical specialty society such as The American College of Surgeons? How often does the surgeon perform the type of surgery you need? How many such surgeries has the doctor performed? Has the doctor explained the surgical procedure to you, as well as the risk factors, side effects, quality of life and success rates you might expect? It is important to you and your family to have a good working relationship with whichever doctor you choose, and to be able to communicate and be involved in decisions regarding your medical care. Always trust your own feelings
When you have been diagnosed with a rare form of cancer such as mesothelioma, finding a doctor who is familiar with the disease and its treatment is an important consideration. Health care available at the local level may suffice if you choose “standard” care options such as chemotherapy, however, if you are looking into surgical evaluation or other specialized forms of treatment, it becomes more important to expand your search for doctors who deal with mesothelioma on a regular basis and have experience in the most up to date protocols available.
Second opinions are common when dealing with a rare cancer, and after listening carefully to your primary doctor’s opinions and treatment plans, you may wish to consult with a more specialized physician before making a treatment decision. By doing this, you can feel comfortable that you have explored every avenue possible and have information on every available option. Your primary doctor may be able to refer you to a specialist, or you can do this on your own as a “self referral”. In either case, you should be sure your primary doctor is aware that you are satisfied with the care you have been given thus far, but because of the rarity of the disease, you would like to be as thoroughly informed as possible. No good doctor should feel threatened that you want to seek a second opinion – it is simply being a good consumer.
A “specialist” is a physician who is licensed to practice medicine, has met certain education and training criteria in a specific field and has passed an examination given by a specialty board. These doctors are then “board certified” in their field. A physician may also choose a “subspecialty” to further increase their expertise and become board certified in the subspecialty as well. Nearly all board certified specialists are members of a medical specialty society that relates to their field of specialization.
Following are some examples of specialties and subspecialties as applies to mesothelioma treatment:
Surgery is a specialty that pertains to the treatment of disease by surgical operation on any area of the body. Doctors who conduct these types of surgeries are called general surgeons. An example of a surgical subspecialty would be a thoracic surgeon who deals specifically with diseases of the chest area. Medical Oncology is a subspecialty of internal medicine. Medical oncologists treat cancer and most often manage treatment plans such as chemotherapy. They may also consult with or refer to other types of specialists. Radiation Oncology is a subspecialty of radiology. Radiation oncologists specialize in the use of radiation to treat cancer. In order to make an informed decision when choosing your doctor, consider the following questions:
Does the doctor have the education and training necessary to meet my needs, and does he or she have experience in treating mesothelioma? How many cases of mesothelioma has he or she treated in the past year? In their career? Has the doctor given you information on mesothelioma itself, and on the various treatment options you might be eligible for? Does the doctor listen to your concerns and treat you with respect? Does the doctor encourage you to ask questions and explain things in terms that you understand? When choosing a surgeon, considering the following questions:
Is the surgeon board certified? Does the surgeon belong to a medical specialty society such as The American College of Surgeons? How often does the surgeon perform the type of surgery you need? How many such surgeries has the doctor performed? Has the doctor explained the surgical procedure to you, as well as the risk factors, side effects, quality of life and success rates you might expect? It is important to you and your family to have a good working relationship with whichever doctor you choose, and to be able to communicate and be involved in decisions regarding your medical care. Always trust your own feelings
mesothelioma patients
mesothelioma patients
Fatigue refers to a lack of energy that affects a patient’s ability to function and may cause mental distress. Symptoms include feelings of weakness, exhaustion, weariness, tiredness, etc., and may be psychological and emotional as well as physical. A patient may suffer from either acute or chronic fatigue. Acute fatigue is relatively short-lived, with symptoms both beginning and ending quickly. Chronic fatigue lasts much longer, resisting efforts from the patient to rest and recuperate.
Fatigue occurs in a large portion of cancer patients and those who have had cancer in the past, and may be due to a number of cancer-related reasons. Some common factors include medications, weight loss, diet, pain, breathing difficulties, anemia, tumors, fluctuating hormones, and insomnia. Anxiety, depression, and emotional distress may contribute to fatigue, either as a direct result of the cancer and its treatment or due to the psychological reaction to the diagnosis of cancer and the treatments involved.
Fatigue can also be a result of cancer treatments, such as radiation therapy or chemotherapy. Radiation therapy requires increased energy from the body to repair tissue, which can deplete the body’s energy supply. Fatigue can be a result of chemotherapy, in which the patient may suffer from nausea, vomiting and weight loss and subsequent fatigue as a result. Diet and poor appetite may also be factors, as cancer may cause the body to require more nutrients or affect the body’s ability to process food. The patient may not be getting the necessary nutrients if they are eating less, which is often a result of cancer or treatment related nausea, diarrhea, obstructed bowels, or loss of appetite
Fatigue refers to a lack of energy that affects a patient’s ability to function and may cause mental distress. Symptoms include feelings of weakness, exhaustion, weariness, tiredness, etc., and may be psychological and emotional as well as physical. A patient may suffer from either acute or chronic fatigue. Acute fatigue is relatively short-lived, with symptoms both beginning and ending quickly. Chronic fatigue lasts much longer, resisting efforts from the patient to rest and recuperate.
Fatigue occurs in a large portion of cancer patients and those who have had cancer in the past, and may be due to a number of cancer-related reasons. Some common factors include medications, weight loss, diet, pain, breathing difficulties, anemia, tumors, fluctuating hormones, and insomnia. Anxiety, depression, and emotional distress may contribute to fatigue, either as a direct result of the cancer and its treatment or due to the psychological reaction to the diagnosis of cancer and the treatments involved.
Fatigue can also be a result of cancer treatments, such as radiation therapy or chemotherapy. Radiation therapy requires increased energy from the body to repair tissue, which can deplete the body’s energy supply. Fatigue can be a result of chemotherapy, in which the patient may suffer from nausea, vomiting and weight loss and subsequent fatigue as a result. Diet and poor appetite may also be factors, as cancer may cause the body to require more nutrients or affect the body’s ability to process food. The patient may not be getting the necessary nutrients if they are eating less, which is often a result of cancer or treatment related nausea, diarrhea, obstructed bowels, or loss of appetite
stages of mesothelioma
stages of mesothelioma
Knowing the stage of your mesothelioma will be a factor in helping your doctor formulate a treatment plan. The most definitive and most widely used system is the TNM International Staging System for Diffuse Malignant Pleural Mesothelioma, also called the International Mesothelioma Interest Group System. This system takes into consideration Primary Tumor (T), Lymph Nodes (N) and Metastases (M). There is no established staging system for peritoneal mesothelioma. Peritoneal patients may be staged according to the general TNM system for cancer, or on the bulk of the tumor present (i.e., minimally bulky, moderately bulky, etc.). Because the TNM system is very in depth, and difficult for interpretation by lay persons, following is a simplified version. Stage I is the earliest stage; Stage IV the most advanced.
Stage IMesothelioma involves the right or left pleura and may also have spread to the lung, pericardium or diaphragm on the same side. Lymph nodes are not involved.
Stage IIMesothelioma has spread from the pleura on one side to nearby lymph nodes next to the lung on the same side. It may also have spread into the lung, pericardium or diaphragm on the same side.
Stage IIIMesothelioma has invaded the chest wall, muscle, ribs, heart, esophagus or other organs in the chest on the same side with or without spread to lymph nodes on the same side as the primary tumor.
Stage IVMesothelioma has spread into the lymph nodes in the chest on the side opposite the primary tumor, or extends to the pleura or lung on the opposite side or directly extends into organs in the abdominal cavity or neck. Any distant metastases in included in this stage
Knowing the stage of your mesothelioma will be a factor in helping your doctor formulate a treatment plan. The most definitive and most widely used system is the TNM International Staging System for Diffuse Malignant Pleural Mesothelioma, also called the International Mesothelioma Interest Group System. This system takes into consideration Primary Tumor (T), Lymph Nodes (N) and Metastases (M). There is no established staging system for peritoneal mesothelioma. Peritoneal patients may be staged according to the general TNM system for cancer, or on the bulk of the tumor present (i.e., minimally bulky, moderately bulky, etc.). Because the TNM system is very in depth, and difficult for interpretation by lay persons, following is a simplified version. Stage I is the earliest stage; Stage IV the most advanced.
Stage IMesothelioma involves the right or left pleura and may also have spread to the lung, pericardium or diaphragm on the same side. Lymph nodes are not involved.
Stage IIMesothelioma has spread from the pleura on one side to nearby lymph nodes next to the lung on the same side. It may also have spread into the lung, pericardium or diaphragm on the same side.
Stage IIIMesothelioma has invaded the chest wall, muscle, ribs, heart, esophagus or other organs in the chest on the same side with or without spread to lymph nodes on the same side as the primary tumor.
Stage IVMesothelioma has spread into the lymph nodes in the chest on the side opposite the primary tumor, or extends to the pleura or lung on the opposite side or directly extends into organs in the abdominal cavity or neck. Any distant metastases in included in this stage
mesothelioma chemotherapy
ChemotherapyChemotherapy involves the use of anti-cancer drugs which work by preventing cancer cells from multiplying. In most cases, combinations of drugs are used in order to increase effectiveness. Chemotherapy may be used aggressively to shrink the tumor, or palliatively to relieve symptoms such as shortness of breath or pain. Administration of chemotherapy may be via injection into a vein or muscle, as an oral medication or may sometimes be administered directly into the pleural or peritoneal cavity. Some of the most commonly used drugs include:
Pemetrexed (Alimta) Cisplatin (Platinol) Carboplatin (Paraplatin) Gemcitabine (Gemzar) Doxorubicin (Adriamycin) Mitomycin Raltitrexed (Tomudex) Vinorelbine (Navelbine) New drugs are constantly being investigated by pharmaceutical companies, so you should always feel free to ask your doctor about the newest and most promising drugs. One such drug, Alimta (pemetrexed) was approved in Europe in September, 2005.
RadiotherapyRadiotherapy involves the use of high energy x-rays to kill cancer cells and shrink tumors. It may be used aggressively in conjunction with surgery to help eliminate microscopic seeding which can cause recurrence of disease, or palliatively to treat pain caused by tumors pressing on nerve endings or on another organ. Radiotherapy has also proven effective in preventing tumor seeding at the sites of biopsy or chest tube drainage.
Clinical TrialsThe purpose of clinical trials is to involve patients in finding new and better treatments for their illnesses. Different clinical trials have different goals which may include the testing of new drugs, comparing various ways to treat an illness or the testing of various techniques for cancer prevention. Clinical trials are divided into three phases. Following are short summaries of what each trial phase seeks to accomplish.
Phase I trials are the earliest phase of the clinical trial system. At this point, drugs have only been tested in the laboratory, but have had an effect on destroying cancer cells. These trials enroll only a limited number of participants, and are only available at limited cancer facilities. The goal of Phase I trials is to find the maximum tolerated dosage of the drug without causing serious side effects, which side effects are most common and whether the drug continues to have anti-cancer activity when administered to humans. If the drug is proven to have an effect on cancer at a safe dosage, the drug will then be tested in Phase II trials.
Phase II trials continue to test the safety of drugs or procedures, but also begin to look more closely at their effectiveness for particular types of cancer. These trials accrue somewhat larger numbers of participants, and may be located at more facilities. These trials may be “randomized”, meaning that different groups of participants are chosen by a computer, rather than by a doctor.
Phase III trials compare promising new drugs or procedures with the current standard of treatment. Large numbers of participants from widespread areas are accrued for these trials, and receive either the new treatment or the standard treatment. One of the primary goals of Phase III trials is to determine whether cancer is reduced or slowed by the drugs, how long patients remain stable without progression of disease and how treatment with the drug affects the patient’s quality of life.
If you are interested in participating in a clinical trial for mesothelioma, your doctor should be able to provide you with information on eligibility and availability in your area.
Pemetrexed (Alimta) Cisplatin (Platinol) Carboplatin (Paraplatin) Gemcitabine (Gemzar) Doxorubicin (Adriamycin) Mitomycin Raltitrexed (Tomudex) Vinorelbine (Navelbine) New drugs are constantly being investigated by pharmaceutical companies, so you should always feel free to ask your doctor about the newest and most promising drugs. One such drug, Alimta (pemetrexed) was approved in Europe in September, 2005.
RadiotherapyRadiotherapy involves the use of high energy x-rays to kill cancer cells and shrink tumors. It may be used aggressively in conjunction with surgery to help eliminate microscopic seeding which can cause recurrence of disease, or palliatively to treat pain caused by tumors pressing on nerve endings or on another organ. Radiotherapy has also proven effective in preventing tumor seeding at the sites of biopsy or chest tube drainage.
Clinical TrialsThe purpose of clinical trials is to involve patients in finding new and better treatments for their illnesses. Different clinical trials have different goals which may include the testing of new drugs, comparing various ways to treat an illness or the testing of various techniques for cancer prevention. Clinical trials are divided into three phases. Following are short summaries of what each trial phase seeks to accomplish.
Phase I trials are the earliest phase of the clinical trial system. At this point, drugs have only been tested in the laboratory, but have had an effect on destroying cancer cells. These trials enroll only a limited number of participants, and are only available at limited cancer facilities. The goal of Phase I trials is to find the maximum tolerated dosage of the drug without causing serious side effects, which side effects are most common and whether the drug continues to have anti-cancer activity when administered to humans. If the drug is proven to have an effect on cancer at a safe dosage, the drug will then be tested in Phase II trials.
Phase II trials continue to test the safety of drugs or procedures, but also begin to look more closely at their effectiveness for particular types of cancer. These trials accrue somewhat larger numbers of participants, and may be located at more facilities. These trials may be “randomized”, meaning that different groups of participants are chosen by a computer, rather than by a doctor.
Phase III trials compare promising new drugs or procedures with the current standard of treatment. Large numbers of participants from widespread areas are accrued for these trials, and receive either the new treatment or the standard treatment. One of the primary goals of Phase III trials is to determine whether cancer is reduced or slowed by the drugs, how long patients remain stable without progression of disease and how treatment with the drug affects the patient’s quality of life.
If you are interested in participating in a clinical trial for mesothelioma, your doctor should be able to provide you with information on eligibility and availability in your area.
Inscription à :
Articles (Atom)